A trial to investigate the efficacy and safety of SER-109 in patients with recurrent Clostridium difficile infections

Trial Profile

A trial to investigate the efficacy and safety of SER-109 in patients with recurrent Clostridium difficile infections

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Sponsors Seres Health
  • Most Recent Events

    • 25 Feb 2016 According to Seres Therapeutics media release, the FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations.
    • 09 Feb 2016 According to a Seres Therapeutics media release, results from this study were published in The Journal of Infectious Diseases.
    • 09 Feb 2016 Results were published in a Seres Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top